Mazen Issa, MD
Gastroenterology · Cleveland, OHNPI 1598755464
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,182 of the $2,791 with a category attached, or 78.2%. 24 manufacturers reported payments, led by AbbVie at 35.2% of the total. That places this record below the midpoint for gastroenterology clinicians in OH, where the typical reported total is $2,203.
Across 121 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$983
- Boston Scientific$749
- Novo Nordisk$172
- Pfizer$142
- Echosens North America, Inc.$125
- Takeda Pharmaceuticals U.S.A., Inc.$108
- plus $512 from 18 others
Across 63 payments — averaging $5414.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$183K
- Eli Lilly$120K
- Pfizer$30K
- Ferring Pharmaceuticals AS$8K
What the payments were for
- Travel & lodging$59321%
- Food & beverage$2,18278%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $983 |
| Boston Scientific | 6 | $749 |
| Novo Nordisk | 4 | $172 |
| Pfizer | 8 | $142 |
| Echosens North America, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $108 |
| Madrigal Pharmaceuticals | 3 | $71 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| Intercept Pharmaceuticals, Inc. | 2 | $34 |
| Ironwood Pharmaceuticals, Inc | 2 | $33 |
| Johnson & Johnson | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Braintree Laboratories, Inc. | 2 | $30 |
| Merck | 2 | $30 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Gilead | 1 | $25 |
| Lilly USA, LLC | 1 | $24 |
| QOL Medical, LLC | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Evoke Pharma, Inc. | 1 | $20 |
| Vivus LLC | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,791 in reported general payments places this provider in the 50th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 34 | $793,274 |
| Entyvio PenVedolizumab | 12 | $80,866 |
| LinzessLinaclotide | 39 | $28,512 |
| Mesalamine | 33 | $12,612 |
| Pantoprazole Sodium | 583 | $6,659 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 96 | $5,840 |
| Dexlansoprazole DrDexlansoprazole | 11 | $2,875 |
| Sucralfate | 81 | $2,428 |
| Famotidine | 279 | $2,359 |
| CholestyramineCholestyramine (With Sugar) | 12 | $868 |
| Lactulose | 59 | $846 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 54 | $813 |
| Esomeprazole Magnesium | 21 | $590 |
| Omeprazole | 45 | $589 |
| ConstuloseLactulose | 17 | $332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $32 | $793,27434 claims |
| AbbVieLinzess | $983 | $28,51239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Cleveland
- Pierre GholamCleveland$1.6M
- Florian RiederCleveland$396K
- Stanley CohenCleveland$338K
- Taha QaziCleveland$307K
- Vu NguyenCleveland$145K
- Benjamin CohenCleveland$144K
- Imad AsaadCleveland$141K
- Ronnie FassCleveland$123K
- Amit BhattCleveland$118K
- Anjana PillaiCleveland$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.